苏黄止咳胶囊对过敏性鼻炎-哮喘综合征急性发作期患者气道炎症的影响

Effects of Suhuang Zhike Capsule on inflammation of airways in patients with allergic rhinitis and asthma syndrome

目的探讨苏黄止咳胶囊对过敏性鼻炎-哮喘综合征急性发作期患者气道炎症的影响。方法选择2016年6月至2017年9月在华北理工大学附属医院住院治疗的过敏性鼻炎-哮喘综合征患者80例作为观察对象,采取前瞻性队列研究,应用随机数字表法分为治疗组和对照组,每组患者各40例。对照组采用常规抗炎、化痰及平喘治疗等治疗方案;治疗组在常规抗炎、化痰及平喘治疗等治疗方案上口服苏黄止咳胶囊。治疗前及治疗2周后对比分析两组患者鼻部症状及哮喘临床症状变化,同时测定呼出气一氧化氮、血及诱导痰中嗜酸性粒细胞计数的变化情况。结果与对照组比较,治疗组治疗前呼出气一氧化氮、血及诱导痰中嗜酸性粒细胞计数差异无统计学意义[(161.45±4.67)×10^-9比(163.12±4.56)×10^-9,(1.59±0.53)×10^9/L比(1.60±0.51)×10^9/L,(1.11±0.06)×10^9/L比(1.18±0.09)×10^9/L;t值分别为0.10、0.44、1.75,P均>0.05]。治疗组治疗后呼出气一氧化氮、血及诱导痰中嗜酸性粒细胞计数均明显低于其治疗前水平[(30.86±5.54)×10^-9比(161.45±4.67)×10^-9,(0.32±0.05)×10^9/L比(1.59±0.53)×10^9/L,(0.06±0.02)×10^9/L比(1.11±0.06)×10^9/L;t值分别为91.32、41.63、51.77,P均<0.01],治疗组鼻部症状控制有效率85.0%(34/40)明显高于对照组62.5%(25/40)(χ^2=5.23,P<0.05);哮喘临床症状控制有效率明显高于对照组[(90.0%(36/40)比72.5%(29/40),χ^2=4.02,P<0.05)]。结论苏黄止咳胶囊可明显改善过敏性鼻炎-哮喘综合征急性发作期患者气道炎症反应,联合常规治疗方案有助于提高疗效。

Objective To investigate the effect of Suhuang Zhike Capsule on airway inflammation in patients with acute episode of allergic rhinitis and asthma syndrome.Methods Eighty patients with allergic rhinitis and asthma syndrome were admitted to North China University of Science and Technology Affiliated Hospital from June 2016 to September 2017.A prospective cohort study was carried out and randomly divided into treatment group and control group with 40 patients in each group.The control group was treated with conventional anti-inflammatory,expectorant and antiasthmatic therapy,while the treatment group was treated with Suhuang Zhike Capsule.The changes of nasal symptoms and asthma clinical symptoms in the two groups were compared before and after treatment,and the changes of nitric oxide in exhaled air,eosinophils in blood and induced sputum were measured.Results Compared with the control group,there was no significant difference in the number of eosinophils in the exhaled nitric oxide,eosinophil count in blood and induced sputum before treatment in the treatment group((161.45±4.67)×10^-9 vs.(163.12±4.56)×10^-9,(1.59±0.53)×10^9/L vs.(1.60±0.51)×10^9/L,(1.11±0.06)×10^9/L vs.(1.18±0.09)×10^9/L;t values were 0.10,0.44,1.75,respectively,all P>0.05).After treatment,the exhaled nitric oxide,eosinophil count in blood and induced sputum in the treatment group were significantly lower than those before treatment((30.86±5.54)×10^-9 vs.(161.45±4.67)×10^-9;(0.32±0.05)×10^9/L vs.(1.59±0.53)×10^9/L;(0.06±0.02)×10^9/L vs.(1.11±0.06)×10^9/L,t values were 91.32,41.63,51.77,respectively,all P<0.01).In the treatment group,the effective rate of nasal symptom control was 85.0%(34/40)significantly higher than 62.5%(25/40)in the control group(χ^2=5.23,P<0.05),and the effective rate of asthma clinical symptom control was significantly higher than that in the control group(90.0%(36/40),72.5%(29/40),χ^2=4.02,P<0.05).Conclusion Suhuang Zhike capsule can obviously improve the airway inflammatory response of patients with allergic rhinitis asthma syndrome in the acute attack stage,and the combination of conventional treatment plan is helpful to improve the curative effect.